Trajan Wealth LLC Increases Stake in Cencora, Inc. $COR

Trajan Wealth LLC grew its position in shares of Cencora, Inc. (NYSE:COR) by 6.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 143,475 shares of the company’s stock after buying an additional 8,169 shares during the period. Cencora accounts for 2.0% of Trajan Wealth LLC’s holdings, making the stock its 11th biggest holding. Trajan Wealth LLC’s holdings in Cencora were worth $48,459,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Oakworth Capital Inc. purchased a new position in shares of Cencora in the 4th quarter valued at about $26,000. Elyxium Wealth LLC purchased a new position in Cencora during the 4th quarter valued at about $27,000. Archer Investment Corp increased its holdings in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares in the last quarter. Optima Capital LLC purchased a new position in Cencora during the 4th quarter valued at about $31,000. Finally, IAG Wealth Partners LLC purchased a new position in Cencora during the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on COR shares. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. William Blair started coverage on shares of Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. UBS Group lifted their price target on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Barclays lifted their price target on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Finally, Robert W. Baird lowered their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Twelve investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $380.25.

Cencora Price Performance

COR opened at $264.79 on Thursday. The company’s 50 day simple moving average is $308.93 and its 200 day simple moving average is $337.71. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market capitalization of $51.52 billion, a PE ratio of 20.31, a P/E/G ratio of 1.23 and a beta of 0.64.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same period in the prior year, the business posted $4.42 earnings per share. Cencora’s revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 17.76 EPS for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.